先天性肾病综合征 中国就医指南

Congenital Nephrotic Syndrome (CNS) is a rare, genetically driven kidney disorder presenting within the first three months of life—typically before birth or in the neonatal period. It is characterized by massive proteinuria, severe hypoalbuminemia, hyperlipidemia, and generalized edema, resulting from structural and functional abnormalities in the glomerular filtration barrier, particularly involving podocyte slit diaphragm proteins. The most common genetic cause is autosomal recessive mutations in the NPHS1 gene encoding nephrin, accounting for ~80% of Finnish-type CNS; other implicated genes include NPHS2 (podocin), WT1, LAMB2, and PLCE1. Pathogenesis centers on disrupted podocyte architecture and signaling, leading to loss of size- and charge-selective filtration, permitting uncontrolled leakage of plasma proteins—especially albumin—into the urine. This triggers compensatory hepatic synthesis of lipoproteins and acute-phase reactants, perpetuating edema, thrombotic risk, infection susceptibility, and growth failure. Epidemiologically, CNS is exceedingly rare, with an estimated incidence of 1–3 per 100,000 live births globally; it is markedly higher in Finland (1:8,200) due to a founder NPHS1 mutation. Risk factors are predominantly genetic—consanguinity increases autosomal recessive transmission risk—and prenatal indicators such as elevated maternal alpha-fetoprotein, placental enlargement (>25% of birth weight), and fetal ascites may raise suspicion. Without intervention, CNS carries high mortality in infancy due to sepsis, thromboembolism, malnutrition, and end-stage kidney disease (ESKD). Quality of life is profoundly impacted: affected infants require intensive nutritional support, frequent albumin infusions, anticoagulation, immunosuppression (in select non-genetic or atypical cases), and early nephrectomy followed by dialysis or transplantation. Caregivers face immense psychosocial, financial, and logistical burdens—including prolonged hospitalizations, home nursing, and lifelong immunosuppressive management post-transplant. Even with successful kidney transplantation, recurrence is rare in monogenic CNS but long-term outcomes depend on timing of transplant, infection control, and neurodevelopmental surveillance. Early molecular diagnosis via genetic testing (e.g., targeted NGS panels) is critical to guide prognosis, avoid ineffective immunosuppression, and enable family counseling and prenatal testing in subsequent pregnancies.

# 先天性肾病综合征治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用人群：确诊为芬兰型或非芬兰型先天性肾病综合征（CNF/N-CNF）、蛋白尿<3.5g/d、eGFR≥60mL/min/1.73m²、无严重血栓或感染并发症者。

• •基础药物治疗（激素+免疫抑制剂）：泼尼松+环孢素A/他克莫司，年均药费 12,000–28,000元；
• •支持治疗：ACEI/ARB降蛋白尿、利尿剂、抗凝（低分子肝素）、营养支持，年均 6,000–15,000元；
• •必需检查费（年均）：24h尿蛋白定量、血清白蛋白、脂质谱、肾功能、电解质、血药浓度监测等，2,800–4,500元。

二、手术/核心介入方案

适用条件：进展至终末期肾病（eGFR<15mL/min）、反复严重感染或血栓、药物难治性大量蛋白尿伴营养衰竭。

• •肾脏替代治疗：

- 腹膜透析（CAPD/APD）：年均 58,000–72,000元；

• •肾移植术（根治性方案）：术前评估（HLA配型、心肺功能、感染筛查等）12,000–18,000元；手术+住院+首年免疫抑制剂总费用 220,000–350,000元。

三、特殊复杂/晚期方案

耐药型CNF合并肾静脉血栓、严重感染或移植后复发：需个体化生物制剂（利妥昔单抗）、血浆置换（单次3,200–4,800元，疗程4–6次），年均综合费用 150,000–400,000元。

四、方案快速选择指南

• •预算有限/早期患儿：首选保守治疗（年支出≤4万元）；
• •中产家庭/进展期：优先腹膜透析过渡，同步登记肾移植；
• •重症/多并发症：直接启动移植评估，医保报销后自付约8–15万元/年。